6.28

7.17% 0.42

After Hours: 6.28

Enanta Pharmaceuticals Inc (ENTA)

Overview News Price History Option Chain Financials Discussions Forecast

Enanta Pharmaceuticals Inc stock is traded at $6.28, with a volume of 635.58K. It is up +7.17% in the last 24 hours and down -30.84% over the past month. Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Previous Close:

$5.86

Open:

$5.84

24h Volume:

635.58K

Relative Volume:

2.46

Market Cap:

$133.10M

Revenue:

$73.62M

Net Income/Loss:

$-138.24M

P/E Ratio:

-0.9949

EPS:

-6.3125

Net Cash Flow:

$-99.19M

1W Performance:

+4.15%

1M Performance:

-30.84%

6M Performance:

-45.06%

1Y Performance:

-26.29%

1-Day Range:

$5.72

$6.31

1-Week Range:

$5.70

$6.56

52-Week Range:

$5.70

$17.80

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Name

Enanta Pharmaceuticals Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

617 607 0800

Address

500 ARSENAL STREET, WATERTOWN, MA

Employee

131

Twitter

@EnantaPharma

Next Earnings Date

2024-11-25

Latest SEC Filings

ENTA's Discussions on Twitter

Compare ENTA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENTA Enanta Pharmaceuticals Inc	6.28	133.10M	73.62M	-138.24M	-99.19M	-6.56
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-09-23	Downgrade	JP Morgan	Neutral → Underweight
Aug-08-23	Downgrade	Jefferies	Buy → Hold
Dec-09-22	Initiated	H.C. Wainwright	Buy
Jul-06-22	Upgrade	Evercore ISI	In-line → Outperform
Jun-01-22	Upgrade	Evercore ISI	Underperform → In-line
Oct-07-21	Initiated	Jefferies	Buy
Sep-09-21	Initiated	SVB Leerink	Mkt Perform
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral
Nov-24-20	Initiated	Evercore ISI	Underperform
Aug-28-20	Resumed	ROTH Capital	Buy
Aug-26-20	Initiated	Piper Sandler	Overweight
Jul-27-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Mar-17-20	Upgrade	Robert W. Baird	Neutral → Outperform
Nov-22-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-26-19	Downgrade	JP Morgan	Neutral → Underweight
May-24-19	Initiated	Wolfe Research	Outperform
Apr-23-19	Upgrade	Berenberg	Hold → Buy
Dec-13-18	Initiated	Berenberg	Hold
Jun-06-18	Initiated	ROTH Capital	Buy
Feb-08-18	Downgrade	JP Morgan	Overweight → Neutral
Jan-02-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-21-17	Reiterated	RBC Capital Mkts	Outperform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Jul-11-17	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Apr-28-16	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Feb-09-16	Reiterated	Barclays	Underweight
Oct-23-15	Downgrade	Barclays	Equal Weight → Underweight
Oct-23-15	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform

View All

Enanta Pharmaceuticals Inc Stock (ENTA) Latest News

Dec 19, 2024

Fmr LLC Purchases 7,839 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World

Dec 19, 2024

Dec 17, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 27,597 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World

Dec 17, 2024

Charles Schwab Investment Management Inc. Sells 1,649 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World

Dec 17, 2024

Dec 15, 2024

Enanta Pharmaceuticals' SWOT analysis: RSV pipeline progress buoys stock outlook - Investing.com

Dec 15, 2024

Dec 14, 2024

(ENTA) Technical Data - Stock Traders Daily

Dec 14, 2024

Dec 13, 2024

Enanta stock touches 52-week low at $6.36 amid market challenges - Investing.com Canada

Dec 13, 2024

FY2025 Earnings Estimate for ENTA Issued By Leerink Partnrs - Defense World

Dec 13, 2024

Dec 12, 2024

Leerink Partnrs Has Positive Outlook of ENTA FY2025 Earnings - MarketBeat

Dec 12, 2024

Dec 11, 2024

Enanta Pharmaceuticals CFO Paul Mellett sells shares worth $20,883 By Investing.com - Investing.com Canada

Dec 11, 2024

Enanta Pharmaceuticals' chief scientific officer sells $20,883 in stock By Investing.com - Investing.com Canada

Dec 11, 2024

Enanta Pharmaceuticals CFO Paul Mellett sells shares worth $20,883 - Investing.com

Dec 11, 2024

Enanta Pharmaceuticals' chief scientific officer sells $20,883 in stock - Investing.com

Dec 11, 2024

Point72 Asset Management L.P. Buys New Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat

Dec 11, 2024

Dec 10, 2024

Enanta Pharmaceuticals chief scientific officer sells shares worth $20,883 By Investing.com - Investing.com Nigeria

Dec 10, 2024

Enanta Pharmaceuticals' chief product strategy officer sells $18,400 in stock By Investing.com - Investing.com Canada

Dec 10, 2024

Enanta Pharmaceuticals CEO sells $41,444 in stock By Investing.com - Investing.com Nigeria

Dec 10, 2024

Enanta Pharmaceuticals CFO sells shares worth $20,883 - Investing.com

Dec 10, 2024

Enanta Pharmaceuticals CEO sells $41,444 in stock - Investing.com

Dec 10, 2024

Enanta Pharmaceuticals chief business officer sells $18,400 in stock By Investing.com - Investing.com Nigeria

Dec 10, 2024

Enanta Pharmaceuticals CFO sells shares worth $20,883 By Investing.com - Investing.com Nigeria

Dec 10, 2024

Enanta Pharmaceuticals chief business officer sells $18,400 in stock - Investing.com

Dec 10, 2024

Enanta Pharmaceuticals' chief product strategy officer sells $18,400 in stock - Investing.com

Dec 10, 2024

Enanta’s zelicapavir shows promise in paediatric respiratory syncytial virus trial - Yahoo Finance

Dec 10, 2024

Dec 09, 2024

Enanta logs phase II RSV win with zelicapavir - BioWorld Online

Dec 09, 2024

Enanta Pharmaceuticals Sees Positive Topline Results for RSV Drug Trials - MarketWatch

Dec 09, 2024

LogoEnanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) - Business Wire

Dec 09, 2024

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) - BioSpace

Dec 09, 2024

Enanta's RSV Drug Zelicapavir Shows Strong Antiviral Effects in Landmark Pediatric Trial - StockTitan

Dec 09, 2024

Dec 06, 2024

Enanta Pharma to Unveil Breakthrough RSV Pediatric Trial ResultsKey Phase 2 Data Coming - StockTitan

Dec 06, 2024

Dec 05, 2024

Enanta stock touches 52-week low at $7.99 amid market challenges - Investing.com Nigeria

Dec 05, 2024

Dec 04, 2024

Erste Asset Management GmbH Purchases New Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat

Dec 04, 2024

Dec 01, 2024

Enanta Pharmaceuticals (FRA:9EP) 3-Year FCF Growth Rate : -9.20% (As of Sep. 2024) - GuruFocus.com

Dec 01, 2024

Caligan Partners LP Cuts Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat

Dec 01, 2024

Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $19.50 - MarketBeat

Dec 01, 2024

Nov 30, 2024

Enanta Pharmaceuticals Initiates Phase 1 Study of MRSA Infection Candidate EDP-788 - Marketscreener.com

Nov 30, 2024

Enanta Pharmaceuticals (NASDAQ:ENTA) Receives Market Outperform Rating from JMP Securities - Defense World

Nov 30, 2024

Analysts Have Been Trimming Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target After Its Latest Report - Simply Wall St

Nov 30, 2024

Nov 29, 2024

Enanta Pharmaceuticals’ Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility - Yahoo Finance

Nov 29, 2024

Nov 28, 2024

Enanta Pharmaceuticals' SWOT analysis: RSV pipeline and cash position fuel stock outlook - Investing.com

Nov 28, 2024

ENTA (Enanta Pharmaceuticals) Accounts Receivable : $6.65 Mil (As of Sep. 2024) - GuruFocus.com

Nov 28, 2024

Robert W. Baird Has Lowered Expectations for Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price - Defense World

Nov 28, 2024

Nov 27, 2024